Surface plasmon resonance biosensors for detection of Alzheimer disease biomarker

Hegnerová, Kateřina; Bocková, Markéta; Vaisocherová, Hana; Krištofiková, Zdeňka; Říčný, Jan; Řı́pová, Daniela; Homola, Jiřı́

doi:10.1016/j.snb.2008.09.006

Cited by 70 publications

(38 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For analyte concentration determination and kinetic studies of biomolecular interactions, the attractive features of SPR include the high sensitivity, label-free and real-time measurements, relatively simple procedure, and low sample consumption 22–24. Homola and coworkers employed SPR to detect the 17β–hydroxysteroid dehydrogenase type 10 (17β–HSD10) enzyme and a peptidic analog in artificial CSF solutions 27. The interaction between 17β–HSD10 and Aβ has been suggested as a possible cause for mitochondrial dysfunction in AD 11.…”

Section: Introductionmentioning

confidence: 99%

Regenerable and Simultaneous Surface Plasmon Resonance Detection of Aβ(1−40) and Aβ(1−42) Peptides in Cerebrospinal Fluids with Signal Amplification by Streptavidin Conjugated to an N-Terminus-Specific Antibody

et al. 2010

View full text Add to dashboard Cite

A major constituent in the deposit in Alzheimer's disease (AD) patient brain is the aggregates/ fibrils of amyloid-β (Aβ) peptides containing 39-43 amino acids. The total Aβ levels and the concentration ratio between the most abundant Aβ(1-40) peptide and the more aggregation-prone Aβ(1-42) in body fluids (e.g., cerebrospinal fluid or CSF) have been suggested as possible criteria for early diagnosis of AD. By immobilizing capture antibodies specific to the two peptides in separate fluidic channels, surface plasmon resonance (SPR) has been used to quantify Aβ(1-40) and Aβ(1-42) present in CSF samples collected from AD patients and healthy donors. With signal amplification by streptavidin conjugated to an antibody that is selective to the common Nterminus of the Aβ peptides, concentrations as low as 20 pM can be readily measured. The range of Aβ peptide concentrations measurable by this method spans four orders of magnitude. The ability of regenerating the sensor surface for repeated measurements not only improves the reproducibility, but also enhances the sample throughput. Our data reveal that the ratio of Aβ(1-40) concentration versus Aβ(1-42) concentration in CSF samples from AD patients is almost twice as high as that from healthy persons. In contrast to the commonly used enzyme-linked immunosorbent assay (ELISA), SPR obviates the need of a more expensive and less stable enzyme conjugate and the use of carcinogenic substrate for the signal detection, and allows the binding events to be monitored in real time.

show abstract

Section: Introductionmentioning

confidence: 99%

Regenerable and Simultaneous Surface Plasmon Resonance Detection of Aβ(1−40) and Aβ(1−42) Peptides in Cerebrospinal Fluids with Signal Amplification by Streptavidin Conjugated to an N-Terminus-Specific Antibody

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Monoclonal/polyclonal β-A antibody against 17-HSD10 peptide was immobilized onto SAM platform via amino coupling chemistry to detect synthetic peptide of 14 amino acids from the 17-HSD10 molecule (residues 133–146) and whole enzyme 17-HSD10. Author also detected 17-HSD10 enzyme in artificial CBF at ng/ml levels (Hegnerová et al 2009). Cheng at al reported that many human protein misfolding disorders in AD are related with β-sheet-rich amyloid fibrils accumulation (Cheng et al 2013).…”

Section: State-of-the-art Of β-A Detectionmentioning

confidence: 98%

“…An alkylthiolates-SAM based SPR biosensing method was prepared for label-free detection of 17 β-hydroxysteroid dehydrogenase type 10 (17-HSD10) (Hegnerová et al 2009). The 17-HSD10 is a multifunctional mitochondrial enzyme associated with AD and investigated as a target marker for the diagnostics of AD.…”

Section: State-of-the-art Of β-A Detectionmentioning

confidence: 99%

“…Few electrochemical systems, (Rushworth et al 2014; Veloso et al 2014), ELISA assays (Schenk et al 1999; Yang et al 2003), optical immunoassays, and SPR (Haes et al 2004; Hegnerová et al 2009) based approaches have been investigated for β-A detection in real samples. As of now, it is difficult to use the state-of-the art facility and expertise at POC application due to need of high expertise and sophisticated laboratory set-up.…”

Section: Towards β-A Detection At Point-of-care Applicationmentioning

confidence: 99%

See 1 more Smart Citation

Nano-biosensors to detect beta-amyloid for Alzheimer's disease management

Kaushik

Jayant

Tiwari

et al. 2016

Biosensors and Bioelectronics

151

View full text Add to dashboard Cite

Beta-amyloid (β-A) peptides are potential biomarkers to monitor Alzheimer’s diseases (AD) for diagnostic purposes. Increased β-A level is neurotoxic and induces oxidative stress in brain resulting in neurodegeneration and causes dementia. As of now, no sensitive and inexpensive method is available for β-A detection under physiological and pathological conditions. Although, available methods such as neuroimaging, enzyme-linked immunosorbent assay (ELISA), and polymerase chain reaction (PCR) detect β-A, but they are not yet extended at point-of-care (POC) due to sophisticated equipments, need of high expertise, complicated operations, and challenge of low detection limit. Recently, β-A antibody based electrochemical immuno-sensing approach has been explored to detect β-A at pM levels within 30–40 minutes compared to 6–8 hours of ELISA test. The introduction of nano-enabling electrochemical sensing technology could enable rapid detection of β-A at POC and may facilitate fast personalized health care delivery. This review explores recent advancements in nano-enabling electrochemical β-A sensing technologies towards POC application to AD management. These analytical tools can serve as an analytical tool for AD management program to obtain bio-informatics needed to optimize therapeutics for neurodegenerative diseases diagnosis management

show abstract

“…Other examples of biosensors include the detection of drugs -typically challenging due to their low molecular weight -hormones, allergy markers as well as markers for infarction [1]. Interestingly, Homola's group is currently developing strategies to detect Alzheimer biomarkers in cerebrospinal cord liquid which are expected to help in unraveling the mechanisms behind this disease [67,68]. Chardin et al [69] used SPRi to monitor multiple interactions of the complex antibody responses to three major milk allergens (α-lactalbumin, β-lactoglobulin and casein) immobilized on a gold-activated chip surface; ELISA was used as the reference method.…”

Section: Medical Diagnosticsmentioning

confidence: 99%

Surface Plasmon Resonance: Advances of Label-Free Approaches in The Analysis of Biological Samples

et al. 2014

View full text Add to dashboard Cite

Surface plasmon resonance sensors have made vast advancements in the sensing technology and the number of applications achievable. New developments in surface plasmon resonance sensors have gained considerable momentum promoted by the urgent needs of fast, reliable and label-free methods for detection and quantification of analytes in molecular biology, medicine and other life sciences. However, even if enormous improvements in the limits of detections have been achieved, this technology still faces important challenges to be translated to clinical practice or in-field measurements. This paper reviews the important recent advances of this technology for the label-free detection in real biological samples and we discussed the key challenges to be overcome to transit from prototypes to commercial biosensors.

show abstract

Surface plasmon resonance biosensors for detection of Alzheimer disease biomarker

Cited by 70 publications

References 15 publications

Regenerable and Simultaneous Surface Plasmon Resonance Detection of Aβ(1−40) and Aβ(1−42) Peptides in Cerebrospinal Fluids with Signal Amplification by Streptavidin Conjugated to an N-Terminus-Specific Antibody

Regenerable and Simultaneous Surface Plasmon Resonance Detection of Aβ(1−40) and Aβ(1−42) Peptides in Cerebrospinal Fluids with Signal Amplification by Streptavidin Conjugated to an N-Terminus-Specific Antibody

Nano-biosensors to detect beta-amyloid for Alzheimer's disease management

Surface Plasmon Resonance: Advances of Label-Free Approaches in The Analysis of Biological Samples

Contact Info

Product

Resources

About